Genetic and somatic testing reveals what you can’t see but really want to know about prostate cancer, allowing patients and providers to make the best treatment decisions.
Prostate Cancer Prognostic Test
Prostate cancer is personal and treatment should be too. The Prolaris Test is for any untreated man with prostate cancer and helps patients and providers answer pressing clinical questions like:
I’m a patient
I’m a provider
You may have inherited more than just your eye color from your parents.
The MyRisk® Hereditary Cancer Test is a genetic test that identifies mutations to determine if you have an inherited form of cancer. MyRisk testing helps qualify patients for new, personalized treatments – like targeted therapies and understand if you are at risk of developing a secondary cancer.
The Prolaris Test is a molecular diagnostic test that helps determine the aggressiveness of a prostate cancer tumor to determine if a patient can appropriately watch their cancer in favor of active surveillance or if they should pursue treatment.
The MyRisk Test screens for genetic variants linked to inherited cancers, helping identify individuals at increased risk based on their personal or family history. It can also assist in selecting patients for targeted therapies like PARP inhibitors and immunotherapy.
A somatic test that assesses 500+ genes, as well as key biomarkers like MSI, TMB and PD-L1, to determine if a patient’s tumor may be appropriate for novel therapies or clinical trials.
100% Medicare coverage for qualified patients
Majority of patients face no out-of-pocket costs for the Prolaris Test.1
If you receive a bill and your expected out-of-pocket cost exceeds your budget, we have ways to help.
Education
Prolaris Testing Guide
Understanding my Prolaris Test results
Understanding your PSA levels
Being a caregiver
Prostate Cancer Symptoms and Treatment
Patient blogs
Resources
Prolaris Test Request Form
Patient Record Request
Understanding the Prolaris report
Ask a genetic counselor
The Modern Urologist Podcast
Prolaris Technical Specifications
While urologists and radiation oncologists are increasingly turning to genetic testing for prostate cancer management, many are still relying on traditional tools…
Prostate cancer is a very common disease, roughly 1 in 8 American men will be diagnosed with prostate cancer during their lifetime. Receiving a prostate…
SALT LAKE CITY, Aug. 15, 2023 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN) a leader …
©2025 Myriad Genetics, Inc. Myriad Genetics, MyRisk, Precise Tumor, Prolaris and their respective logos, are registered trademarks of Myriad Genetics, Inc. and its subsidiaries in the United States and other jurisdictions.